Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
AOTI, Inc. ( (GB:AOTI) ) has provided an announcement.
AOTI, Inc. has announced that its Topical Wound Oxygen (TWO2®) therapy will be included in the NHS Supply Chain framework agreement for Advanced Wound Care 2025, effective September 1, 2025. This inclusion follows a health economic study showing that TWO2® therapy can significantly reduce diabetic foot care costs for the NHS in England. The therapy is expected to provide substantial cost savings and improve patient outcomes by reducing wound recurrence, hospitalizations, and amputations. The NHS framework agreements aim to streamline procurement and deliver cost savings while maintaining high clinical standards.
More about AOTI, Inc.
AOTI, Inc., founded in 2006 and based in Oceanside, California, and Galway, Ireland, specializes in innovative solutions for severe and chronic wounds. The company’s primary product, the patented non-invasive Topical Wound Oxygen (TWO2®) therapy, significantly reduces healthcare costs and improves patients’ quality of life by reducing the recurrence of Diabetic Foot Ulcers (DFUs), hospitalizations, and amputations. This therapy is approved by regulatory bodies in the US, Europe, UK, Canada, China, Australia, and Saudi Arabia.
YTD Price Performance: -25.68%
Average Trading Volume: 32,523
Technical Sentiment Signal: Strong Buy
Current Market Cap: £87.75M
See more insights into AOTI stock on TipRanks’ Stock Analysis page.